Patients’ Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.

Eur J Pain. 2019 Jul;23(6):1117-1128. doi: 10.1002/ejp.1378. Epub 2019 Mar 18. Perrot S1, Lantéri-Minet M2,3. Abstract BACKGROUND: Patient-Reported Outcome (PRO) instruments have been developed to evaluate pain management in daily practice; the Patients’ Global Impression of Change (PGIC) is particularly

Two-pore-domain potassium channels and molecular mechanisms underlying migraine

Biologie Aujourd’hui 2019;213(1-2):51-57. doi: 10.1051/jbio/2019020. Epub 2019 Jul 5. [Two-pore-domain potassium channels and molecular mechanisms underlying migraine] Perrine Royal, Pablo Ávalos Prado, Brigitte Wdziekonski, Guillaume Sandoz PMID: 31274103 DOI: 10.1051/jbio/2019020 Abstract Migraine is a common, disabling neurological disorder with genetic, environmental and hormonal

QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France.

Curr Med Res Opin. 2019 Mar;35(3):417-426. doi: 10.1080/03007995.2018.1558850. Epub 2019 Jan 7. Lantéri-Minet M1,2, Perrot S3. Abstract OBJECTIVE: To describe the characteristics of patients treated with the capsaicin 8% patch, prescribing conditions, long-term effects of repeat treatment on pain intensity

Effects of systemic inhibitors of Acid-Sensing Ion Channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine.

Br J Pharmacol. 2018 Nov;175(21):4154-4166. doi: 10.1111/bph.14462. Epub 2018 Sep 22. Verkest C1,2,3, Piquet E3,4, Diochot S1,2,3, Dauvois M1, Lanteri-Minet M3,4,5, Lingueglia E1,2,3, Baron A1,2,3. Abstract BACKGROUND AND PURPOSE: Acid-sensing ion channels (ASICs) are neuronal proton sensors emerging as potential

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.

Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22. Reuter U1, Goadsby PJ2, Lanteri-Minet M3, Wen S4, Hours-Zesiger P5, Ferrari MD6, Klatt J5. Abstract BACKGROUND: A substantial proportion of patients with migraine does not respond to, or cannot tolerate,